Recent 8-K filings for RLAY

• May 19, 2026 12:45 UTC other_material materiality 0.70 positive item 7.01item 8.01item 9.01

  Relay Therapeutics Announces Initial Phase 2 Data for Zovegalisib in Vascular Anomalies Showing 60% Response Rate

  60% of 20 evaluable patients achieved a volumetric response by BICR at first MRI in Phase 2 ReInspire trial; 95% experienced lesion reduction.

• May 05, 2026 23:59 UTC earnings materiality 0.65 positive item 2.02item 9.01

  Relay Therapeutics Q1 2026 net loss $73.3M; FDA BTD for zovegalisib; cash $642M

  FDA granted Breakthrough Therapy designation to zovegalisib+fulvestrant for PIK3CA-mutant HR+/HER2- advanced breast cancer.

• Apr 27, 2026 23:59 UTC other_material materiality 0.75 positive item 7.01item 8.01item 9.01

  Relay Therapeutics reports 44% ORR for zovegalisib triplet; plans Phase 3 in frontline breast cancer

  ORR of 44% (15/34) in heavily pre-treated, CDK4/6-experienced patients; 85% tumor reduction.

• Mar 16, 2026 23:59 UTC other_material materiality 0.65 positive item 7.01item 8.01item 9.01

  Relay Therapeutics reports zovegalisib + fulvestrant Phase 1/2 data: 11.1 mo median PFS at RP3D

  Median PFS of 11.1 months (95% CI 7.3-13.0) in 57 evaluable PI3Kα-mutated HR+/HER2- mBC patients.

• Mar 11, 2026 23:59 UTC other_material materiality 0.20 neutral item 5.03item 9.01

  Relay Therapeutics adopts exclusive federal forum for securities claims

  Board approved second amended and restated bylaws effective March 6, 2026.

• Feb 26, 2026 23:59 UTC earnings materiality 0.65 neutral item 2.02item 9.01

  Relay Therapeutics reports Q4 net loss $0.32/share; cash $554.5M; zovegalisib milestones in 2026

  Q4 2025 net loss $54.9M ($0.32/share) vs $76.0M ($0.45) in Q4 2024; full year net loss $276.5M ($1.61/share).

• Feb 03, 2026 23:59 UTC regulatory materiality 0.75 positive item 7.01item 8.01item 9.01

  Relay's zovegalisib granted FDA Breakthrough Therapy Designation for PIK3CA-mutant breast cancer

  FDA granted Breakthrough Therapy Designation to zovegalisib + fulvestrant for PIK3CA-mutant HR+/HER2- advanced breast cancer after CDK4/6i.

• Nov 06, 2025 23:59 UTC earnings materiality 0.65 neutral item 2.02item 5.02item 7.01item 9.01

  Relay Therapeutics Q3 net loss $74.1M, cash $596.4M; appoints two directors

  Net loss $74.1M ($0.43 per share) vs $88.1M ($0.63) in Q3 2024.

• Aug 07, 2025 23:59 UTC earnings materiality 0.75 neutral item 2.02item 9.01

  Relay Therapeutics Q2 net loss narrows to $70.4M; initiates Phase 3 ReDiscover-2 trial

  Net loss of $70.4M ($0.41 per share) vs $92.2M ($0.69) in Q2 2024.

• Jun 11, 2025 23:59 UTC leadership materiality 0.45 neutral item 5.02item 9.01

  Relay Therapeutics appoints Claire Mazumdar to board; Jami Ruben resigns

  Jami Ruben resigned as Class III director and Audit Committee member effective June 8, 2025; no dispute or disagreement.

• Jun 06, 2025 23:59 UTC other materiality 0.10 neutral item 5.07

  Relay Therapeutics stockholders elect directors and approve auditor at 2025 annual meeting

  Alexis Borisy elected class II director with 80.7M votes for, 43.0M withheld.

• Jun 04, 2025 23:59 UTC other_material materiality 0.60 neutral item 1.01item 1.02

  Relay Therapeutics terminates Binney St lease early, signs Kendall Square lease; saves ~$16M in rent

  Paid $2.5M modification fee and transferred FF&E to landlord to terminate Binney St lease early.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.75 · Median 0.65 · Most common event other_material

5 positive 0 negative 7 neutral

source · RLAY on sec.gov